Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given an average rating of “Moderate Buy” by the five analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $55.00.

A number of research firms recently commented on SLN. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Monday, March 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Wednesday, June 17th. Jefferies Financial Group raised shares of Silence Therapeutics to a “strong-buy” rating in a report on Wednesday, March 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st.

Institutional Investors Weigh In On Silence Therapeutics

Hedge funds have recently modified their holdings of the stock. EHP Funds Inc. bought a new stake in shares of Silence Therapeutics in the 3rd quarter worth approximately $55,000. XTX Topco Ltd purchased a new position in Silence Therapeutics in the 4th quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. grew its stake in Silence Therapeutics by 65.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after buying an additional 5,421 shares in the last quarter. Citadel Advisors LLC purchased a new position in Silence Therapeutics in the 3rd quarter valued at approximately $112,000. Finally, Massar Capital Management LP purchased a new position in Silence Therapeutics in the 2nd quarter valued at approximately $115,000. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Stock Down 3.5%

Silence Therapeutics stock opened at $7.27 on Wednesday. Silence Therapeutics has a 52 week low of $4.19 and a 52 week high of $8.40. The company’s 50 day moving average price is $6.87 and its two-hundred day moving average price is $6.12. The stock has a market cap of $343.40 million, a P/E ratio of -4.57 and a beta of 1.48.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings results on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). The company had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. On average, equities analysts anticipate that Silence Therapeutics will post -0.95 EPS for the current year.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.